Last reviewed · How we verify
NCT05180799
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Phase 1, PHASE2 trial testing BA3071 in NSCLC in 320 participants. Participants enrolled and being followed up; not accepting new ones.
19 March 2025
Quick facts
| Lead sponsor | BioAtla, Inc. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 320 |
| Start date | 3 August 2022 |
| Primary completion | 19 March 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 12 locations across United States, Australia |
Drugs / interventions tested
- BA3071
- Nivolumab (nivolumab) — full drug profile →
- Pembrolizumab (pembrolizumab) — full drug profile →
- Pemetrexed (Alimta) — full drug profile →
Conditions studied
Sponsor
BioAtla, Inc. — full company profile →
Who can join
18 and older, any sex, with NSCLC or Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.
Cheng W, Kang K, Zhao A, Wu Y. · · 2024 · cited 110× · PMID 39068460 · DOI 10.1186/s13045-024-01581-2
Verify or expand the search:
- PubMed search for NCT05180799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other BioAtla, Inc. trials
Trials by the same sponsor.
- NCT05808634 — Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. · Phase 1 · recruiting
- NCT05271604 — A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Ne · Phase 2 · completed
- NCT04681131 — CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC · Phase 2 · completed
- NCT03504488 — CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) · Phase 1, PHASE2 · completed
- NCT03425279 — CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05180799 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioAtla, Inc.
- Last refreshed: 15 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05180799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing